Based on the Allena Pharmaceuticals Inc stock forecasts from 3 analysts, the average analyst target price for Allena Pharmaceuticals Inc is USD 3.00 over the next 12 months. Allena Pharmaceuticals Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Allena Pharmaceuticals Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Allena Pharmaceuticals Inc’s stock price was USD 0.12.
In order to treat patients in the United States with uncommon and severe metabolic and kidney illnesses, Allena Pharmaceuticals, Inc., a biopharmaceutical business, discovers, develops, and commercialises oral enzyme therapies. Alln-346, a brand-new urate-degrading enzyme for patients with hyperuricemia and gout in the context of advanced chronic renal disease, is the company’s flagship product candidate. The business was established in 2011 and has its corporate headquarters in Newton, Massachusetts.
Most Recent Analyst Ratings:
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|---|---|---|---|---|
 |
Downgraded by | B. Riley |
USD 3
|
2022-03-22 | |
|
|
Reiterated by | HC Wainwright | 2022-03-21 | ||
|
|
Reiterated by | Ladenburg Thalmann | 2022-03-21 | ||
|
|
Target Lowered by | B. Riley |
USD 4 » USD 3
|
2022-01-24 |
What we like:
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What we don’t like:
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
